HOUSTON, Texas — Moleculin Biotech, Inc. (Nasdaq: MBRX) (“Moleculin” or the “Company”) today announced that dosing has been completed in Part A of its pivotal Phase 2/3 MIRACLE trial evaluating Annamycin in combination with cytarabine (AnnAraC) for the treatment of adults with relapsed or refractory acute myeloid leukemia (R/R AML)....

SAN DIEGO, Calif. — Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the launch of educational resources designed to help healthcare providers strengthen their understanding of classic congenital adrenal hyperplasia. The offerings include bootCAHmp®, an interactive, educational course that builds foundational clinical knowledge, and DiscoverCAH™, a virtual patient case experience that enables healthcare providers to apply...

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain —Prilenia Therapeutics B.V. and Ferreri today announced the publication online, on October 22, 2026, of a new manuscript, in Neurology®, the medical journal of the American Academy of Neurology, presenting a post hoc analysis providing Phase 3 clinical trial evidence of the association between...